Scedosporium apiospermum as a rare cause of central skull base osteomyelitis

Päivi Jalava-Karvinen a,e, Mikko Nyman b, Maria Gardberg c,e, Inka Harju d, Ulla Hohenthal a,e, Jarmo Oksi a,e

a Department of Infectious Diseases, Division of Medicine, Turku University Hospital, Turku, Finland
b Department of Emergency Radiology, Medical Imaging Center of Southwest Finland, Turku University Hospital, Turku, Finland
c Department of Pathology, Turku University Hospital, Turku, Finland
d Department of Clinical Microbiology, Turku University Hospital, Turku, Finland
e Faculty of Medicine, Turku University, Turku, Finland

Article info

Article history:
Received 13 March 2016
Received in revised form 31 March 2016
Accepted 6 April 2016
Available online 7 April 2016

Keywords:
Scedosporium apiospermum
Central skull base osteomyelitis
Mold infection

1. Introduction

Scedosporium apiospermum (teleomorph state Pseudallescheria boydii) is a mold commonly found in the environment. It is capable of causing invasive infections in both immunocompromised and competent individuals [1–3]. In patients with normal immune system, S. apiospermum typically causes local infections such as skin ulcers or arthritis [3] but as a result of immunosuppression, the pathogen can invade to vessel walls and blood circulation and cause disseminated infection [4,5]. S. apiospermum has a predilection to the central nervous system (CNS) and patients with brain abscesses have been reported [5,6]. Neutropenia, use of corticosteroids, and diabetes are risk factors for opportunistic Scedosporium infections [1,3–5]. Treatment is challenging and requires immune system reconstitution, aggressive surgical treatment and prolonged antifungal treatment. Guidelines rely on the experience gathered from single case reports. Voriconazole (VCZ) is suggested as the first line therapy of infections caused by these multidrug resistant molds [7].

Central skull base osteomyelitis (SBO) is a rare life-threatening condition originating from external auditory canal or less frequently from sinonasal infections [8–10]. It is defined as an osteitis of the temporal bone and skull base, including the bony labyrinth, the medial part of the petrosa, the sphenoidal and occipital bones and the clivus, even reaching the infratemporal fossa [11]. The infection may spread through the skull base forming granulomas and abscesses in the brain tissue and also lower cranial nerves can get affected [12,13]. In the diagnosis of SBO and its complications magnetic resonance imaging (MRI) is the most important method [14]. The most frequent etiology of SBO is bacterial but 20% to 50% are fungal [8]. Fungal SBO is most often caused by Aspergillus spp. [15].

We report a patient with S. apiospermum ear infection, central SBO, and finally, mycotic occlusion of the internal carotid artery (ICA) leading to death.

2. Case

A 48-year old man had suffered from type I diabetes for 35 years. His blood glucose had been poor for years. He had several diabetic complications including retinopathy and nephropathy. Hemodialysis had been started in September, 2013. He was using oral prednisolone 20 mg daily for painful chronic calcification wounds on his legs.

In December, 2013 (day 0), the patient complained of pain in his right ear. On the examination, there was an occluding mass inside the ear canal. Pathological anatomical diagnosis (PAD)
showed an ulcer with granulation tissue. Bacterial cultures remained negative but no fungal tests were performed. Computed tomographic scanning (day 20) showed large soft tissue mass inside the mastoid sinus, middle ear and bony ear canal with bone erosions in the right jaw joint. Although the PAD suggested an abscess with fungal hyphae inside, no systemic antimicrobial treatment was commenced. Because of the worsening headache, drainage of the right ear, and temporal impairment of the left upper limb function, he visited the emergency, in February 2014 (day 80).

He had no signs of an acute infection, but complained of double images. Right-sided abducens nerve paresis was observed. C-reactive protein was 33 mg/l (normal < 10 mg/l), and white blood cell count $8.0 \times 10^3$/l (normal 3.4–8.2 $\times 10^3$/l). MRI showed a cerebral lesion that was interpreted as ischemic or infective. There was a suspicion of vessel wall inflammation in the right ICA at the level of skull base (Fig. 1). The cerebrospinal fluid (CSF) contained no leukocytes but protein was elevated at 800 mg/l (normal 150–450 mg/l). Polymerase chain reaction (PCR) showed weak positivity for *Aspergillus nidulans* considered as a contamination by the laboratory. Fungal and bacterial cultures remained negative.

Empirical treatment with intravenous (iv) ceftriaxone, iv vancomycin, oral rifampicin, and iv fluconazole (FCZ) 400 mg daily was started. Neurological symptoms were suspected to be due to partial seizures resulting from a cerebral infarction. He needed opiates because of severe headache.

On day 97, MRI revealed progression of infective areas in the skull base. Inflammation of the right ICA wall was stronger with occlusion and aneurysmatic enlargement which was suspected to be mycotic. On the right frontal and parietal lobes, multiple small focal abscesses were detected (Fig. 1). Due to the worsening situation and the PCR finding of *A. nidulans* FCZ was switched to oral VCZ (200 mg bid). Ceftriaxone was switched to meropenem. On day 101, an operation involving right sphenoidal and ethmoidal sinuses as well as right medial and superior concha, was performed. PAD showed no fungal hyphae but a possibility of a healing fungal infection.

A mold was isolated from a sample taken from the sphenoidal sinus and was identified as *S. apiospermum* on the basis of typical colony morphology and shape of the conidiophores. The identification was confirmed by matrix-assisted laser-desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry, using Microflex LT instrument, MALDI Biotyper software version 3.1 and Filamentous Fungi Library database version 1.0 (supplied by Bruker Daltonics, Bremen, Germany). Specimen preparation was carried out as described by Schulthess et al. [16]. Antifungal resistance testing was performed at the Mycological Unit of the Clinical Microbiology Laboratory of Helsinki University Hospital (HUSLAB). The isolate showed minimum inhibitory concentrations of 0.38 for VCZ, 4 for posaconazole (PCZ), 32 for itraconazole and 12 for amphotericine B. The serum concentration of VCZ with both oral and iv (200 mg bid) administrations remained markedly below the suggested therapeutic concentration 2–5.5 mg/l. On day 121, VCZ dosing was switched back to oral 300 mg bid. VCZ concentration reached the level of 1.7 mg/l and patient’s markedly improved condition made us to believe in the ongoing therapy. On day 135, MRI showed disappearing of the cortical lesions but the skull base involvement remained unchangeable. The non-enhancing mass occluding the ICA was larger (Fig. 1). The patient was discharged to an outpatient hospital on day 149 with oral VCZ and meropenem. He had no pain or problems with his ear and was scheduled for regular visits to the departments of infectious diseases and otolaryngology.

On day 162, patient’s liver function tests (LFTs) appeared to be elevated: gamma-glutamyl transpeptidase 3722 U/l (normal 15–115 U/l), alkaline phosphatase 1291 U/l (normal 35 – 105 U/l), alanine aminotransferase 88 U/l (normal 10–70 U/l), and bilirubin 41 $\mu$mol/l (normal $<$ 21 $\mu$mol/l). Meropenem was discontinued with no improvement on LFTs. On day 174, VCZ was switched to oral PCZ (400 mg bid) with no improvement on LFTs. The serum PCZ concentration of 0.4 mg/l (0.1–5 ml/l) was reached. Finally, antifungal treatment was discontinued because of the concern for patient’s liver. An attempt was made to acquire isavuconazole (ICZ), a new azole-group antifungal at phase III clinical trials, probably with equal effectiveness but fewer side effects than the older azoles. MRI showed that cortical abscesses had almost disappeared and infective changes in the skull base were improving. However, the right ICA occlusion was still present and the non-enhancing mass in the vessel lumen was now almost at the level of middle cerebral artery (MCA) bifurcation.

On day 207, the patient contacted the emergency because of headache and dizziness. On examination, he still had abducens nerve palsy. CSF analysis revealed 2021 leukocytes/ml (normal 4–10 leukocytes/ml), no leukocytes but protein was elevated at 800 mg/l (normal 150–450 mg/l). Fungal polymerase chain reaction (PCR) showed weak positivity for *Aspergillus nidulans* considered as a contamination by the laboratory. Fungal and bacterial cultures remained negative.

Antifungal resistance testing was performed at the Mycological Unit of the Clinical Microbiology Laboratory of Helsinki University Hospital (HUSLAB). The isolate showed minimum inhibitory concentrations of 0.38 for VCZ, 4 for posaconazole (PCZ), 32 for itraconazole and 12 for amphotericine B. The serum concentration of VCZ with both oral and iv (200 mg bid) administrations remained markedly below the suggested therapeutic concentration 2–5.5 mg/l. On day 121, VCZ dosing was switched back to oral 300 mg bid. VCZ concentration reached the level of 1.7 mg/l and patient’s markedly improved condition made us to believe in the ongoing therapy. On day 135, MRI showed disappearing of the cortical lesions but the skull base involvement remained unchangeable. The non-enhancing mass occluding the ICA was larger (Fig. 1). The patient was discharged to an outpatient hospital on day 149 with oral VCZ and meropenem. He had no pain or problems with his ear and was scheduled for regular visits to the departments of infectious diseases and otolaryngology.

On day 162, patient’s liver function tests (LFTs) appeared to be elevated: gamma-glutamyl transpeptidase 3722 U/l (normal 15–115 U/l), alkaline phosphatase 1291 U/l (normal 35 – 105 U/l), alanine aminotransferase 88 U/l (normal 10–70 U/l), and bilirubin 41 $\mu$mol/l (normal $<$ 21 $\mu$mol/l). Meropenem was discontinued with no improvement on LFTs. On day 174, VCZ was switched to oral PCZ (400 mg bid) with no improvement on LFTs. The serum PCZ concentration of 0.4 mg/l (0.1–5 ml/l) was reached. Finally, antifungal treatment was discontinued because of the concern for patient’s liver. An attempt was made to acquire isavuconazole (ICZ), a new azole-group antifungal at phase III clinical trials, probably with equal effectiveness but fewer side effects than the older azoles. MRI showed that cortical abscesses had almost disappeared and infective changes in the skull base were improving. However, the right ICA occlusion was still present and the non-enhancing mass in the vessel lumen was now almost at the level of middle cerebral artery (MCA) bifurcation.
suffered from diabetes and terminal uremia and was using oral prednisolone. Previously, patients with underlying HIV infection and central SBO caused by *S. apiospermum* have been reported [17,18]. One of these was successfully treated with itraconazole and the other died without effective treatment [17,18]. As in other mold infections, the severity of the underlying condition and degree of immunosuppression markedly influence on the outcome of the patient. Vasoo et al. treated their 51-year-old diabetic patient with right-sided otorrhea, cranial nerve palsies and SBO caused by *S. apiospermum* with VCZ for six months. Despite of extensive bony erosions, their patient remained in remission without further antifungal medication [19]. The possibility of this rare fungal infection should be recalled, because the treatment of severe fungal infections with amphotericin B will not be effective.

In the present case, the diagnosis was made very late mainly because the possibility of such a rare condition had not occurred to anybody’s mind. Samples for fungal culture should have been taken in December, 2013. FCZ was started as a part of an empiric treatment because fungi were considered to be partly involved. FCZ is not effective against filamentous fungi why the treatment choice was not optimal. If amphotericin B had been started, it would have not worked either. Infectious disease specialist was consulted in December, 2013. FCZ was started as a part of an empiric treatment possibly due to the patient being a fast metabolizer. The outer ear infection initially detected and treated was only the tip of the iceberg. During treatment, the mold infection was irreversibly spreading inside the right ICA leading to the fatal rupture of the proximal MCA. Retrospectively, we can see how the process progressed despite of the apparently effective treatment with VCZ (Fig. 1). Hyperbaric oxygen might be an option as an adjunctive therapy but it was not used in our case. The prognosis of disseminated *S. apiospermum* infection is dismal with the mortality rate of CNS infection being 74% according to case reports [5]. Although our case represents rather local spread than wider dissemination, this patient case with an unhappy ending highlights the insidious nature of *Scedosporium* infection.

**Conflict of interest**

There is none.

**Acknowledgements**

We thank Turku University Hospital EVO Grant 13900 for support when writing this paper.

**References**

[1] M.M. Campa-Thompson, J.A. West, J.M. Guileyardo, C.W. Spak, L.M. Sloan, S.C. Beal, Clinical and morphologic findings in disseminated *Scedosporium apiospermum* infections in immunocompromised patients, Bayl. Univ. Med. Cent. Proc. 27 (2014) 253–256.

[2] J.C. Watson, J.S. Myserson, M.R. Bullock, True fungal mycotic aneurysm of the basilar artery: a clinical and surgical dilemma, Cerebrovasc. Dis. 9 (1999) 50–53.

[3] P. Koehler, D. Tacke, O.A. Cornelly, Bone and joint infections by *Mucorales*, *Scedosporium*, *Fusarium* and even rarer fungi, Crit. Rev. Microbiol. 9 (2014) 93–108.

[4] P. Munoz, M. Marin, P. Tornero, P. Martin Rabanad, M. Rodriguez-Cresixens, E. Bouza, Successful outcome of *Scedosporium apiospermum* disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy, Clin. Infect. Dis. 31 (2000) 1499–1501.

[5] A.S. Kantarciously, J. Guarro, G.S. de Hoog, Central nervous system infections by members of the *Pseudallescheria boydii* species complex in healthy and immunocompromised hosts: epidemiology, clinical characteristics and outcome, Mycoses 51 (2008) 275–290.

[6] I.K. Mellinghoff, D.J. Winston, G. Mukwagya, D.J. Schiller, Treatment of *Scedosporium apiospermum* Brain Abscesses with Posaconazole, Clin. Infect. Dis. 34 (2002) 1648–1650.

[7] A.M. Tortorano, M. Richardson, E. Roidides, A. van Diepeningen, M. Cair, P. Munoz, et al., ESCMID and ECMM joint guidelines on diagnosis and management of *hyalohyphomycosis: Fusarium spp.*, *Scedosporium* spp. and others, Clin. Microbiol. Infect. 20 (Suppl. 3) (2014) S27–S46.

[8] C.C. Blyth, L. Gomes, T.C. Sorrell, M. da Cruz, A. Sud, S. Chen, Skull base osteomyelitis: fungal vs. bacterial infection, Clin. Microbiol. Infect. 17 (2011) 306–311.

[9] A.K. Johnson, P.S. Batra, Central skull base osteomyelitis: an emerging clinical entity, Laryngoscope 124 (2014) 1084–1088.

[10] J. Rubin, B.F. Barnsletter, V.L. Yu, The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations, Lancer Infect. Dis. 4 (2004) 34–39.

[11] G.J. Ridder, C. Breunig, J. Kaminsky, J. Pfeiffer, Central skull base osteomyelitis: new insights and implications for diagnosis and treatment, Eur. Arch. Otorhinolaryngol. 272 (2015) 1269–1276.

[12] C.-N. Chen, Y.-S. Chen, T.-H. Teh, C.-H. Hsu, F.-Y. Tseng, Outcomes of malignant external otitis: survival vs mortality, Acta Oto-Laryngol. 130 (2010) 89–94.

[13] H. Patmore, A. Jebreel, S. Uppal, C.H. Raine, P. McWhinnie, Skull base infection presenting multiple lower cranial nerve palsies, Am. J. Otolaryngol. 31 (2010) 276–280.

[14] P.C. Chang, N.J. Fischbein, R.A. Holliday, Central skull base osteomyelitis in patients without otitis externa: imaging findings, ANJR Am. J. Neuroradiol. 24 (2003) 1130–1136.

[15] S.E. Kountakis, J.V. Kemper Jr, J. Rubin, B.F. Barnsletter, J. Chang, D.J.M. DiMaio, B.F. Barnsletter, V.L. Yu, The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations, Lancet Infect. Dis. 4 (2004) 34–39.

[16] C.-N. Chen, Y.-S. Chen, T.-H. Yeh, C.-H. Hsu, F.-Y. Tseng, Outcomes of malignant external otitis: survival vs mortality, Acta Oto-Laryngol. 130 (2010) 89–94.

[17] H. Patmore, A. Jebbreel, S. Uppal, C.H. Raine, P. McWhinnie, Skull base infection presenting multiple lower cranial nerve palsies, Am. J. Otolaryngol. 31 (2010) 276–280.

[18] P.C. Chang, N.J. Fischbein, R.A. Holliday, Central skull base osteomyelitis in patients without otitis externa: imaging findings, ANJR Am. J. Neuroradiol. 24 (2003) 1130–1136.

[19] C.L. Slack, D.W. Watson, M.J. Abzub, C. Shaw, K.H. Chan, Fungal mastoiditis in immunocompromised children, Arch. Otolaryngol. Head Neck Surg. 125 (1999) 73–75.

[20] S. Vasoo, S.B. Yeo, P.L. Lim, B.S. Anq, D.C. Lye, Efficacy of voriconazole for *Scedosporium apiospermum* skull base osteomyelitis: case report and literature review, Int. J. Antimicrob. Agents 31 (2008) 184–185.